News

Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results

  • Late breaking presentation at World Federation of Hemophilia (WFH) World Congress on investigational development program in Hemophilia A; development candidate nomination anticipated in mid-year 2024; 12-month non-human primate durability data expected in 2H 2024
    05/14/2024

3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire

  • Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion from $5.3 billion in 2023.
    05/02/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

The price of Metagenomi, Inc. Common Stock (MGX) is 7.01 and it was updated on 2024-05-16 13:00:48.

Currently Metagenomi, Inc. Common Stock (MGX) is in undervalued.

News
    
News

Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems

  • Enhances strategic flexibility and control of key gene editing technologies and programs Enhances strategic flexibility and control of key gene editing technologies and programs
    Wed, May. 01, 2024

Metagenomi to Present at Upcoming Scientific Meetings

  • -   Oral Presentation at World Federation of Hemophilia (WFH) World Congress,  April 23, 2024 -   Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8 & 9, 2024 EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: a late breaking oral presentation at The World Federation of Hemophilia (WFH) World Congress, taking place April 21 – 24, 2024 in Madrid, Spain and two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.
    Mon, Apr. 08, 2024

Metagenomi Reports Business Updates and Full Year 2023 Financial Results

  • Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month nonhuman primate durability data in 2H 2024
    Wed, Mar. 27, 2024

Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference

  • EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Metageno­mi, Inc. (Nas­daq: MGX), a pre­ci­sion genet­ic med­i­cines com­pa­ny com­mit­ted to devel­op­ing cura­tive ther­a­peu­tics for patients using its pro­pri­etary, com­pre­hen­sive metage­nomics-derived gene edit­ing tool­box, today announced that Brian C. Thomas, CEO & Founder, will participate in a panel titled, “Emerging Genetic Therapy Approaches,” during the 44th Annual Cowen Healthcare Conference on Wednesday, March 6, 2024 from 12:50-1:50 PM ET in Boston.
    Thu, Feb. 29, 2024

This Biotech IPO Stock Just Took a Tumble, But Don't Give Up on It Yet

  • Metagenomi just raised $94 million in its initial public offering. It now has enough money to last it for a few years.
    Mon, Feb. 19, 2024
More Headlines
News

Insider Buying: Taking a Controlling Stake in a Struggling Retailer?

  • The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to Florida to take advantage of the better income tax environment.
  • 02/18/2024

Metagenomi Announces Closing of Initial Public Offering

  • EMERYVILLE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced the closing of its previously announced initial public offering of 6,250,000 of its common stock at a price to the public of $15.00 per share. The aggregate gross proceeds to Metagenomi from the offering were approximately $93.75 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Metagenomi has granted the underwriters a 30-day option to purchase up to an additional 937,500 of its common stock at the initial public offering price less underwriting discounts and commissions.
  • 02/13/2024

Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut

  • Shares of Metagenomi Technologies , a genetic medicines company backed by Bayer Healthcare and Moderna , slumped 32% in their Nasdaq debut on Friday.
  • 02/09/2024

Moderna-backed Metagenomi cuts US IPO valuation target to $563 mln

  • Genetic medicines company Metagenomi Technologies MGX.O said on Thursday it is aiming for a valuation of $563 million in its U.S. initial public offering (IPO), a number that is at the low end of its initial target range.
  • 02/08/2024

Metagenomi Announces Pricing of Initial Public Offering

  • EMERYVILLE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (“Metagenomi”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a price to the public of $15.00 per share. The gross proceeds to Metagenomi from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $93,750,000. All of the shares are being offered by Metagenomi. In addition, Metagenomi has granted the underwriters a 30-day option to buy an additional 937,500 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.
  • 02/08/2024
Unlock
MGX Ratings Summary
MGX Quant Ranking